Table 5. Improvements in physician assessed congestive symptoms and signs and patient self-assessed global clinical status after 4-day of treatment.

	Tolvaptan (N = 46)	Placebo (N = 45)	p value*
Physician assessed heart failure symptoms and signs
Jugular venous distension	14 (30.4%)	11 (24.4%)	0.6398
Lower limb edema	31 (67.4%)	26 (57.8%)	0.3905
Pulmonary congestion	22 (47.8%)	19 (42.2%)	0.6751
Pulmonary rales	17 (37.0%)	14 (31.1%)	0.6595
Physician assessed dyspnea	34 (73.9%)	30 (66.7%)	0.2087
Patient self-assessed heart failure symptoms
Mean change of global clinical status score form baseline#	18.26 ± 23.89	23.32 ± 25.42	0.3565
Patient self-assessed dyspnea	41 (89.1%)	36 (80.0%)	0.7717

* The distribution of congestive symptoms severity grading at baseline and at the end of study, and corresponding changes from baseline were determined and compared between the two groups by proportional odds model. ^# Global clinical status score was based on a visual analog scale.